NRX-101

DRUG6 trials

Conditions

Bipolar DepressionMajor DepressionSuicidal IdeationSuicidal Ideation and BehaviorTreatment Resistant DepressionTreatment Resistant Depression (TRD)Treatment-Resistant Depression

Early Phase 1

Single Day of Ultra-accelerated TMS With a Single Dose of NRX-101

Not yet recruitingNCT07785102

Mclean HospitalMajor Depression

Start: 2026-09-01End: 2027-03-31Target: 30Updated: 2026-08-25

Phase 2

NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

CompletedNCT03395392

NeuroRx, Inc.Bipolar Depression, Suicidal Ideation and Behavior

Start: 2022-05-12End: 2024-03-30Updated: 2024-05-08

NRX101 Glx Biomarker Validation Study

CompletedNCT03402152

NeuroRx, Inc.Bipolar Depression, Suicidal Ideation

Start: 2018-11-01End: 2021-06-01Updated: 2022-08-09

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

Not yet recruitingNCT07227103

NeuroRx, Inc.Treatment Resistant Depression, Treatment Resistant Depression (TRD)

Start: 2026-09-01End: 2028-03-31Target: 400Updated: 2026-06-24

Phase 3

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

Active, not recruitingNCT03396068

NeuroRx, Inc.Bipolar Depression, Suicidal Ideation

Start: 2019-12-01End: 2024-12-31Target: 72Updated: 2024-01-19

Unknown Phase

NRX-101 Expanded Access

NCT05779267

NeuroRx, Inc.Treatment-Resistant Depression

Updated: 2026-09-17

Related Papers

NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial.

2023-08-1315 citations